D-Bal MAX is a revolutionary new muscle-building supplement that will put you on the fast track to building lean muscle and ...

Tallmadge, Ohio, May 01, 2025 (GLOBE NEWSWIRE) -- Following Over 90 Days of Personal Experience, Here’s What Truly Occurred ...

Comprehensive Healthcare today announced the expansion of its permanent supportive housing program in Sunnyside with the opening of Vista Del Sol-2 (VDS-2), a 20-unit long-term residential housing ...

The live webcasts of the fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at ...

To that end, the ACELYRIN Board recommends that stockholders vote “FOR” the merger with Alumis in connection with the upcoming Special Meeting of Stockholders scheduled for May 13, 2025. Every ...

For the first quarter of 2025, Ascendis Pharma reported a net loss of €94.6 million, or €1.58 per share (basic and diluted) compared to a net loss of €131.0 million, or €2.30 per share (basic and ...

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), today announced that it plans to submit a Q-Submission (“Q-Sub”) to the U.S. Food and Drug Administration (FDA) related to ...

CORAnet® Solutions facilitates interoperability across networks and platforms, giving patients and their families ownership and personal control of their medical records. Our advanced software ensures ...

HNL Lab Medicine invites local artists in grades K–8 to enter its Annual Art Contest by May 31, 2025, for a chance to win a one-year membership to the Da Vinci Science Center or Crayola Experience and ...

The Company’s Class A Ordinary Shares will begin trading on the Nasdaq Global Market on a post-Reverse Stock Split basis under the current ticker symbol “NIVF” at the commencement of trading on May 5, ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ®  platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, ...